Tensha Therapeutics to be acquired by Roche for upfront $115 million cash

11 January 2016

Privately-held US firm Tensha Therapeutics on Monday said it will be acquired by the Swiss drug maker Roche (SIX: ROG) for an upfront cash payment of $115 million to gain access to the company’s early trial stage product, TEN-010, to treat cancer.

Under the terms of the agreement, Tensha’s shareholders will also receive additional contingent payments of up to $420 million based on the achievement of certain predetermined clinical and regulatory milestones. The transaction is anticipated to close in the first quarter of 2016.

James Bradner, founder of Tensha, said: “BET proteins are a highly promising class of therapeutic targets in cancer. BET inhibitors function as targeted therapy in rare cancers with BET gene rearrangements (NUT midline carcinoma), and in common cancers as a means of inhibiting the function of the master growth control genes, such as MYC.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK